Budesonide reverses lung hyperinflation in childhood asthma: a controlled study

N. Neuparth a,b,*, T. Gamboa a, C. Pereira c, J. Rusado Pinto b, A. Rendas a

a Departamento Universitário de Fisiopatologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo de Santana, 130, 1198 Lisboa CODEX, Portugal
b Serviço de Imunoalergologia, Hospital de Dona Estefânia, Lisboa, Portugal
c Serviço Universitário de Fisiologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo de Santana, 130, 1198 Lisboa CODEX, Portugal

Received 26 February 1999; accepted 9 August 1999

Abstract

It was investigated whether inhaled budesonide reduces lung volumes in a group of asthmatic children with lung hyperinflation. Budesonide (800 μg bid, for 2 months) was administered to 12 asthmatic children (mean age, 11.2 ± 3.3 years) with lung hyperinflation (TGV ≥ 130% predicted and/or RV ≥ 140% predicted) in a randomised, placebo controlled, double blind, crossover study. Body plethysmography (panting frequency controlled at 1·s⁻¹) was performed at the beginning, 2 months afterwards (before crossover) and at the end of the study. Budesonide significantly reduced TGV (2.35 ± 0.90 l BTPS or 126 ± 24% predicted) compared with placebo (2.54 ± 1.08 l BTPS, P = 0.014 or 140 ± 21% predicted, P < 0.05). In addition, budesonide significantly increased mean specific conductance (0.06 ± 0.02 cm H₂O⁻¹ 1 s⁻¹ to 0.07 ± 0.01 cm H₂O⁻¹ 1 s⁻¹, P < 0.05). It was concluded that budesonide reduced lung hyperinflation most likely by decreasing airway inflammation. © 1999 Elsevier Science Ireland Ltd. All rights reserved.

Keywords: Asthma; Lung hyperinflation; Bronchial inflammation; Budesonide

1. Introduction

In a clinical context, hyperinflation implies an abnormal increase in the volume of gas in the lungs at the end of tidal expiration [1]. However, when it was attempted to relate hyperinflation with the airway narrowing occurring in asthma, the picture is much less defined as suggested in a recent review [2] which states that, in this context, there is no clear definition of hyperinflation and of its underlying mechanisms. The authors suggest that both altered properties of airways and lung parenchyma are involved in the development of hyperinflation and point to the importance of measuring residual volume (RV), thoracic gas volume (TVG) and total lung capacity (TLC) to understand the underlying pathophysiological mechanisms.

During an acute attack of asthma [3] there is an increase in all lung volumes which is due not only to the expiratory flow limitation but also to the persistent inspiratory muscle contraction throughout expiration, caused by a reflex mechanism from the constricted airways, which increases end-expiratory volume and produces hyperinflation [4–7]. On the other hand, chronic increases of functional residual capacity (FRC), RV and occasionally of TLC can be observed in some asthmatic patients away from the exacerbations of asthma [2,8] but the mechanisms responsible for these changes, such as loss of bronchial-to-parenchyma interdependence, are still under discussion. A prior study performed in seven asthmatic patients, found a decrease in FRC after a week of systemic steroids that was attributed to an improvement of lung elastic recoil [9] as was later demonstrated [10].
Although it is accepted that the treatment with steroids reduces inflammation both in the airways and in the parenchyma [11,12], the authors were not aware of any study relating such treatment with measurements of lung volumes that are dependent, amongst other factors, upon lung elastic recoil. In order to do that, an inhaled steroid was given to a group of hyperinflated asthmatic children and lung volumes were monitored in a controlled study.

2. Material and methods

2.1. Study subjects

Patients were selected from all asthmatics that have performed lung function tests in an Allergy Clinic during 1 year. From these, 13 children with asthma and lung hyperinflation, aged 6–18 years old were included. The diagnosis of asthma was made according to accepted criteria [13]. All patients were free from inhaled and systemic steroids and from an exacerbation of asthma for at least 6 weeks before the beginning of the study. During the study period all patients were only taking inhaled budesonide regularly and a short-acting \( \beta_2 \) agonist in a prn basis.

According to their clinical symptoms and/or to daily medication required, 11 patients were classified as having moderate persistent asthma, whereas two were labelled as mild persistent [14]. Symptoms of asthma were detected for the first time, in average, since 8.5 ± 4.2 years ago, with a range between 3.1 and 17.3 years. Chronic lung hyperinflation was considered whenever TGV was repeatedly (in three different occasions during the previous year) equal or higher than 130% predicted [15] and/or RV was equal or higher than 140% predicted [16]. The predicted values were calculated from Zapletal equations [17].

2.2. Study design

The study was performed in two phases (Phase 1 and Phase 2), with a duration of 4 months. It was a controlled study, double blind, against placebo according to randomisation in two groups (G1 and G2) of six patients each. A crossover was done at the end of Phase 1. Budesonide (400 \( \mu \)g dose \(^{-1}\)) or placebo was administered to each patient through a Turbohaler\textsuperscript{\textregistered} device twice a day. The content of the inhaler was blinded both to patients and investigators. Lung volumes were measured three times during the study — before starting budesonide (day 0), at crossover (day 57) and at the end of the study (day 113). Patients were instructed to avoid taking \( \beta_2 \) agonists during the 12-h period preceding the lung function measurements. An informed consent was obtained from the tutors in every case and the study was approved by the Hospital Ethics Committee.

2.3. Methods

A body plethysmograph MasterLab Jaeger (Würzburg, Germany) was used to measure lung volumes (TGV, RV and TLC) and specific conductance (\( s_{G_{aw}} \)) according to the method described by Ref. [18]. The procedure followed during measurements was that recommended by the European Respiratory Society [19]. Nevertheless, panting frequency was settled at 1 Hz, using a tachometer as a biofeedback signal to the patient, because lung volumes measured by body plethysmography with high panting frequencies are overestimated in asthma [20,21].

2.4. Analysis

The key questions addressed in this study were: did budesonide modify lung volumes (TGV, RV and TLC) and \( s_{G_{aw}} \), compared with placebo? Did lung volumes correlate with airway calibre before and after treatment with budesonide?

Analysis of variance was used to evaluate the effects of budesonide and placebo according to the methods described in Ref. [22]. Each analysis was tested for period effect and for the presence of carry-over. Delta lung volumes (lung volumes after budesonide — lung volumes after placebo) were correlated with delta conductance (\( G_{aw} \)).

3. Results

3.1. Patient characteristics

Distribution by age and sex of the children included in this study is shown on Table 1. One of the patients was excluded because he had an asthma attack treated with oral steroids during placebo phase. For this reason only 12 patients concluded the study. This group had the following mean baseline volumes (Table 2): TGV, 2.7 ± 1.10 l (141 ± 21% pred.); RV, 1.59 ± 0.80 l (170 ± 53% pred.); and TLC, 4.52 ± 1.62 l (118 ± 13% pred.).

3.2. Effect of budesonide on lung volumes

When compared with placebo, only TGV was significantly reduced (\( P < 0.05 \)) after 2 months of inhaled budesonide, from 2.54 ± 1.08 to 2.35 ± 1.08 l. There were no differences between basal volumes and volumes after placebo (Fig. 1).
3.3. Effect of budesonide on airway calibre

As patients were evaluated through body plethysmography, only resistance (or its reciprocal-conductance) was measured. Specific conductance ($sG_{aw}$) after 2 months of budesonide increased significantly ($P < 0.05$) when compared with $sG_{aw}$ after placebo (from $0.06 \pm 0.02$ to $0.07 \pm 0.01$ cm H$_2$O$^{-1}$·s$^{-1}$, Fig. 1). This increase corresponds to a 17% variation.

3.4. Relation between lung volumes and airway calibre

Delta TGV (as defined in Section 2) was significantly correlated with delta $G_{aw}$ ($r = 0.78$, $P < 0.005$, Fig. 2).

### Table 1

<table>
<thead>
<tr>
<th>No.</th>
<th>Age</th>
<th>Sex</th>
<th>TGV</th>
<th>RV</th>
<th>TLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11</td>
<td>F</td>
<td>2.22</td>
<td>120</td>
<td>1.36</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>M</td>
<td>4.40</td>
<td>163</td>
<td>2.84</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>M</td>
<td>1.87</td>
<td>133</td>
<td>1.03</td>
</tr>
<tr>
<td>4</td>
<td>13</td>
<td>F</td>
<td>3.64</td>
<td>181</td>
<td>2.47</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>M</td>
<td>2.51</td>
<td>127</td>
<td>1.56</td>
</tr>
<tr>
<td>6</td>
<td>10</td>
<td>M</td>
<td>2.68</td>
<td>146</td>
<td>0.97</td>
</tr>
<tr>
<td>7</td>
<td>8</td>
<td>F</td>
<td>1.92</td>
<td>129</td>
<td>1.26</td>
</tr>
<tr>
<td>8</td>
<td>7</td>
<td>M</td>
<td>1.60</td>
<td>130</td>
<td>0.96</td>
</tr>
<tr>
<td>9</td>
<td>18</td>
<td>M</td>
<td>4.78</td>
<td>177</td>
<td>3.17</td>
</tr>
<tr>
<td>10</td>
<td>9</td>
<td>F</td>
<td>1.35</td>
<td>122</td>
<td>0.88</td>
</tr>
<tr>
<td>11</td>
<td>11</td>
<td>M</td>
<td>2.17</td>
<td>132</td>
<td>0.99</td>
</tr>
<tr>
<td>12</td>
<td>14</td>
<td>M</td>
<td>3.22</td>
<td>131</td>
<td>1.58</td>
</tr>
<tr>
<td>Mean</td>
<td>12</td>
<td>9M/4F</td>
<td>2.70</td>
<td>141</td>
<td>1.59</td>
</tr>
<tr>
<td>S.D.</td>
<td>3</td>
<td>–</td>
<td>1.10</td>
<td>21</td>
<td>0.80</td>
</tr>
</tbody>
</table>

*M, male; F, female; % Pred, % predicted values; S.D., standard deviation.

### Table 2

$sG_{aw}$ evolution of asthmatic children with lung hyperinflation during the study

<table>
<thead>
<tr>
<th>No.</th>
<th>Basal</th>
<th>After placebo</th>
<th>After budesonide</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cm H$_2$O$^{-1}$·s$^{-1}$</td>
<td>% Pred</td>
<td>cm H$_2$O$^{-1}$·s$^{-1}$</td>
</tr>
<tr>
<td>1</td>
<td>0.082</td>
<td>90</td>
<td>0.067</td>
</tr>
<tr>
<td>2</td>
<td>0.03</td>
<td>48</td>
<td>0.067</td>
</tr>
<tr>
<td>3</td>
<td>0.06</td>
<td>50</td>
<td>0.076</td>
</tr>
<tr>
<td>4</td>
<td>0.028</td>
<td>33</td>
<td>0.047</td>
</tr>
<tr>
<td>5</td>
<td>0.041</td>
<td>48</td>
<td>0.079</td>
</tr>
<tr>
<td>6</td>
<td>0.091</td>
<td>99</td>
<td>0.089</td>
</tr>
<tr>
<td>7</td>
<td>0.05</td>
<td>44</td>
<td>0.049</td>
</tr>
<tr>
<td>8</td>
<td>0.072</td>
<td>52</td>
<td>0.059</td>
</tr>
<tr>
<td>9</td>
<td>0.053</td>
<td>85</td>
<td>0.039</td>
</tr>
<tr>
<td>10</td>
<td>0.063</td>
<td>41</td>
<td>0.028</td>
</tr>
<tr>
<td>11</td>
<td>0.066</td>
<td>64</td>
<td>0.05</td>
</tr>
<tr>
<td>12</td>
<td>0.088</td>
<td>128</td>
<td>0.065</td>
</tr>
<tr>
<td>Mean</td>
<td>0.060</td>
<td>65</td>
<td>0.060</td>
</tr>
<tr>
<td>S.D.</td>
<td>0.021</td>
<td>29</td>
<td>0.018</td>
</tr>
</tbody>
</table>

*% Pred, % predicted values; S.D., standard deviation.

$* P < 0.05$ when compared with post placebo.
a temporary loss of the relationship between small bronchi and parenchyma, thus reducing elastic recoil [27,28]. This is suggested in this study by the fact that a small improvement in airway calibre after budesonide, demonstrated by the increase in $sG_{aw}$, was not accompanied by a change in RV, which remained higher and not different from placebo. This probably means that a higher RV depends not only on airway calibre but also on persistent parenchymal changes such as a reduction in lung elastic recoil that also contributes to the expiratory flow limitation. Similar observations were made by Sekerel et al. [8] who found a reduction of TLC after 8 weeks of treatment with budesonide, 400 µg day$^{-1}$.

A recent study [29] has shown that, in chronic stable asthma, lung volumes assessed by measurements of TLC, can be larger than predicted at the start of adolescence and suggested that this change was due to the mitogenic effect of inflammatory mediators which stimulated alveolar multiplication during childhood. This hypothesis is different from a previous one [30] which explained the hyperinflation in chronic asthmatics by a process of alveolar destruction because of the stretching caused by the trapped gas. In this regard it is interesting to note that the younger cases, also at the beginning of adolescence, had higher baseline values of TLC than the older patients, a finding which agrees with the above mentioned hypothesis. The authors are aware that the measurement of TLC by plethysmography can produce methodological errors, however, they were minimised by a panting frequency $<1$ Hz. So it was confirmed, as others, that TLC is increased in some of these patients with asthma, whether this is caused by
a higher rate of alveolar multiplication or by modelling of lung tissues or both it is not yet clear.

Another explanation for the increase in TLC could be related to an increase in respiratory muscle strength in chronic asthmatics due to the persistent tonic activity of the inspiratory muscle during expiration. Since respiratory pressures have not been measured, the involvement of the respiratory muscles on the genesis of hyperinflation cannot be excluded, although these changes are considered less likely than those of lung parenchyma. However, the authors’ research findings [31], have shown that, at least maximal mouth pressures are similar in children and adolescents with asthma and a group of age matched controls.

The results show that an inhaled steroid, budesonide, can decrease lung volumes in a group of young asthmatics with lung hyperinflation. This reduction in lung volumes was closely related with the increase of airway calibre thus suggesting a major role of airway inflammation in the genesis of chronic lung hyperinflation in asthma.

Acknowledgements

The authors would like to acknowledge Astra Portuguesa for the logistic support given to this study. We would also like to acknowledge Mrs Carole Caswell from Astra Charnwood (GB) for all the help with statistical analysis. This work was supported by a grant from PRAXIS XXI, PSAU/P/SAU/92/96. Drugs supplied by Astra Portuguesa.

References


